Viking Therapeutics is positioned favorably in the oral GLP-1 obesity drug race, with strong Phase 2 results for VK2735. VKTX's oral candidate achieved 12.2% weight loss at the highest dose in 13 weeks, matching or exceeding peers' metrics and showing potential for further improvement. Management will focus Phase 3 dosing on 20-75 mg, balancing efficacy and tolerability while the injectable 78-week Phase 3 Vanquish trial is underway.
Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly's lead in obesity and diabetes treatment should hold for years.
Kelowna, British Columbia – December 30, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the “ Study ” or the “ Lexaria Study ”), recently completed in Australia, focusing on 4 DehydraTECH™ ( “DHT” ) study arms relative to the Rybelsus® control study arm. “We are pleased to report additional data from our first Phase 1b clinical study,” stated Richard Christopher, CEO of Lexaria. “It adds to a growing dataset which showcases the many potential benefits of our platform technology – DehydraTECH.”
KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), recently completed in Australia, focusing on 4 DehydraTECH™ ("DHT") study arms relative to the Rybelsus® control study arm. "We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria.
Analysts predict packaged food manufacturers and fast-food eateries may be pushed to alter more of their goods next year when newly licensed appetite-suppressing GLP-1 tablets become accessible in January 2026.
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss.
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms relative to the Novo Nordisk A/S‘ (NYSE: NVO) Rybelsus (semaglutide) control study arm.
CNBC's Annika Kim Constantino reports on the FDA's approval of the first GLP-1 pill for obesity from Wegovy maker Novo Nordisk.
Novo Nordisk A/S (NYSE:NVO) stock is up 8.8% to trade at $52.37 at last check, after the biopharmaceutical giant received approval from the U.S. Food & Drug Administration (FDA) for the first ever GLP-1 pill.
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings create runway for prospective new 2026 development opportunities KELOWNA, BC / ACCESS Newswire / December 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the " Study " or the " Lexaria Study "), recently completed in Australia, focusing on 4 DehydraTECH ® ( "DHT" ) study arms relative to the Rybelsus® control study arm. "We are extremely pleased to not only have successfully achieved our primary endpoint," stated Richard Christopher, CEO of Lexaria, "but to have also demonstrated obvious superiority in reducing unwanted side effects by as much as approximately half as compared to the world's only approved oral-based GLP-1 medication, Rybelsus ®.
